Pacific Biosciences of California Profit Margin

The latest profit margin for PACB is -81.31% as of September 2026. That compares with -325.02% in the prior-year period — up 75.0% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Pacific Biosciences of California's historical trend and sector peers before judging valuation or financial health.

Over the past year, PACB's profit margin moved from -325.02% to -81.31% — a 75.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pacific Biosciences of California's valuation or profitability profile.

Against Healthcare companies, PACB currently prints -81.31% for profit margin, while the sector average sits near 17.63%. That is roughly 561.3% below the sector mean. Large gaps often invite a closer look at Pacific Biosciences of California's growth, margins, and balance sheet.

Profit Margin shows how effectively Pacific Biosciences of California converts resources into returns. At -81.31%, PACB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -325.02% in the prior-year period — up 75.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PACB's profit margin (-81.31%), review year-over-year change from -325.02%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.